Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01207687 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
A Phase 2 study of Vestibular Schwannoma and Neurofibromatosis Type 2, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 3
- Study locations
NCT01207687 is a Phase 2 study of Vestibular Schwannoma and Neurofibromatosis Type 2 that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 14 participants, below the 50-participant average among 7 other Vestibular Schwannoma trials with a reported enrollment target (72% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT01207687, a Phase 2 study of Vestibular Schwannoma and Neurofibromatosis Type 2, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 3
- Study locations
Study Summary
People who have neurofibromatosis type 2 (NF2) can have tumors that grow on the auditory nerves and cause hearing loss. These tumors are called vestibular schwannomas (VSs), or acoustic neuromas. People with NF2 can also get schwannomas in other parts of their body, as well as tumors called meningiomas and ependymomas. Because VSs can cause hearing loss, many people with NF2 will have treatment to preserve their hearing. This treatment usually involves surgery. Because surgery has risks and is not able to help everyone with VSs, other methods of treatment are being explored. One area of exploration is looking to see if there is a drug that can be taken that might prevent the VSs from growing larger and causing hearing loss or brainstem compression. This study is exploring whether a drug that is approved by the FDA and is currently used to treat other tumors might also work to treat VSs. Based on people who have taken this drug to treat VSs already, there is some reason to think that it might be helpful to certain people with NF2. People enrolled in this study will receive the drug one time every three weeks for one year by infusion. This study will follow subjects over the course of the year that the person is taking the drug and for six months after the drug is stopped. This study is recruiting people who have NF2 and are currently having symptoms of tinnitus, dizziness, and/or hearing loss from their VSs. If you have NF2 and are currently having symptoms caused by your VSs, you may be eligible to participate.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE quality-of-life assessment
- BIOLOGICAL bevacizumab
Study Locations (3)
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
- National Cancer Institute - Rockville
Massachusetts
- Massachusetts General Hospital - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01207687
The ClinicalTrials.gov registry entry for NCT01207687 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 50-participant average among 7 other Vestibular Schwannoma trials with a reported enrollment target (72% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Vestibular Schwannoma appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01207687 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01207687 about?
NCT01207687 is a clinical study titled "Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)". People who have neurofibromatosis type 2 (NF2) can have tumors that grow on the auditory nerves and cause hearing loss. These tumors are called vestibular schwannomas (VSs), or acoustic neuromas. People with NF2 can also get schwannomas in other parts of their body, as well as tumors called meningio...
What is the current status of trial NCT01207687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2010-10. Estimated completion is 2014-03.
What conditions does trial NCT01207687 study?
This clinical trial studies the following conditions: Vestibular Schwannoma, Neurofibromatosis Type 2.
What interventions are being tested in trial NCT01207687?
The interventions under investigation include: laboratory biomarker analysis (OTHER), quality-of-life assessment (PROCEDURE), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01207687?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01207687 being conducted?
This trial has 3 study locations across Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vestibular Schwannoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
ACTIVE NOT RECRUITING · Phase 2
-
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Aspirin in Patients With Vestibular Schwannoma
ACTIVE NOT RECRUITING · Phase 2
-
StableEyes With Active Neurofeedback
RECRUITING · NA
-
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
RECRUITING · Phase 1
-
CI Following VS Removal or Labyrinthectomy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.